Effect of icotinib on human blood lipid contents:a single center retrospective study
Objective To explore the effect of tyrosine kinase inhibitors(TKIs)that can bind to epidermal growth factor receptor(EGFR)on blood lipid in patients.Methods In this study,we retro-spectively reviewed medical record for patients with advanced lung cancer and treated with Icotinib,a first generation of EGFR-TKI,from January 2015 to July 2019.A total of 36 patients who had complete follow-up medical information were recruited and divided into four groups.The changes in blood lipid levels before and after treatment were evaluated.The paired sample Student's t test,analysis of variance(ANOVA)with Bonferroni post hoc test and Chi Square test were performed for data analysis.Results Icotinib could significantly reduce the content of serum total cholesterol(the mean before treatment was 4.886 mmol/L,the mean after treatment was 4.409 mmol/L,t=2.787,P＜0.01),low density lipoprotein(the mean before treatment was 2.957 mmol/L,the mean after treatment was 2.53 mmol/L,t=9.596,P＜0.01)and Apolipoprotein B(the mean before treatment was 1.003 mmol/L,the mean after treatment was 0.900 mmol/L,t=2.828,P＜0.01)after treatment with Icotinib for at least one month[duration of treat-ment,IQR(one month,6 months).Conclusion Icotinib can effectively reduce the lipid content of pa-tients,suggesting that it may be used in the treatment of non-alcoholic fatty liver disease.
Epidermal growth factor receptor inhibitorIcotinibHyperlipidaemiaHyper-cholesteremiaRetrospective study
NETL
NSTL
万方数据
